X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs CADILA HEALTHCARE - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD CADILA HEALTHCARE STRIDES SHASUN LTD/
CADILA HEALTHCARE
 
P/E (TTM) x 32.4 24.1 134.5% View Chart
P/BV x 0.9 6.0 14.3% View Chart
Dividend Yield % 1.1 0.8 147.0%  

Financials

 STRIDES SHASUN LTD   CADILA HEALTHCARE
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
CADILA HEALTHCARE
Mar-17
STRIDES SHASUN LTD/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,275460 277.1%   
Low Rs918305 301.0%   
Sales per share (Unadj.) Rs389.692.1 422.9%  
Earnings per share (Unadj.) Rs28.014.8 188.8%  
Cash flow per share (Unadj.) Rs48.918.5 264.6%  
Dividends per share (Unadj.) Rs4.503.20 140.6%  
Dividend yield (eoy) %0.40.8 49.1%  
Book value per share (Unadj.) Rs303.168.0 445.8%  
Shares outstanding (eoy) m89.421,023.74 8.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.2 67.8%   
Avg P/E ratio x39.225.8 151.8%  
P/CF ratio (eoy) x22.420.7 108.3%  
Price / Book Value ratio x3.65.6 64.3%  
Dividend payout %16.121.6 74.5%   
Avg Mkt Cap Rs m98,036391,581 25.0%   
No. of employees `0005.816.9 34.4%   
Total wages/salary Rs m5,88115,002 39.2%   
Avg. sales/employee Rs Th6,005.95,594.5 107.4%   
Avg. wages/employee Rs Th1,014.0890.1 113.9%   
Avg. net profit/employee Rs Th431.2899.9 47.9%   
INCOME DATA
Net Sales Rs m34,83494,295 36.9%  
Other income Rs m1,6861,286 131.1%   
Total revenues Rs m36,52095,581 38.2%   
Gross profit Rs m6,42819,036 33.8%  
Depreciation Rs m1,8723,750 49.9%   
Interest Rs m2,269450 504.3%   
Profit before tax Rs m3,97316,122 24.6%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,006-3 33,523.3%   
Tax Rs m4701,289 36.5%   
Profit after tax Rs m2,50115,168 16.5%  
Gross profit margin %18.520.2 91.4%  
Effective tax rate %11.88.0 148.0%   
Net profit margin %7.216.1 44.6%  
BALANCE SHEET DATA
Current assets Rs m38,16560,223 63.4%   
Current liabilities Rs m30,40253,058 57.3%   
Net working cap to sales %22.37.6 293.3%  
Current ratio x1.31.1 110.6%  
Inventory Days Days7770 110.8%  
Debtors Days Days10488 118.5%  
Net fixed assets Rs m37,63972,984 51.6%   
Share capital Rs m8941,024 87.3%   
"Free" reserves Rs m26,21068,576 38.2%   
Net worth Rs m27,10569,600 38.9%   
Long term debt Rs m16,37724,684 66.3%   
Total assets Rs m81,168152,207 53.3%  
Interest coverage x2.836.8 7.5%   
Debt to equity ratio x0.60.4 170.4%  
Sales to assets ratio x0.40.6 69.3%   
Return on assets %5.910.3 57.3%  
Return on equity %9.221.8 42.3%  
Return on capital %12.117.9 67.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,46521,280 63.3%   
Fx outflow Rs m4,07610,874 37.5%   
Net fx Rs m9,38910,406 90.2%   
CASH FLOW
From Operations Rs m2,88113,495 21.4%  
From Investments Rs m-7,051-29,103 24.2%  
From Financial Activity Rs m3,38223,158 14.6%  
Net Cashflow Rs m-7887,556 -10.4%  

Share Holding

Indian Promoters % 27.7 74.8 37.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 8.3 455.4%  
FIIs % 8.6 5.9 145.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 11.0 235.5%  
Shareholders   56,241 44,069 127.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   AJANTA PHARMA  FDC LTD.  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare STRIDES SHASUN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Jun 21, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD - FRESENIUS KABI ONCO. COMPARISON

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS